Cannabis giant Tilray Brands, Inc. (NASDAQ:TLRY) announced Wednesday it has obtained second approval for a new medical marijuana extract in Portugal. The medical cannabis extract that got this approval is Tilray Oral Solution THC10:CBD10.
This milestone follows up on the successful approval of Tilray Medical's whole flower THC 18, and approval for the first cannabis extract in Portugal earlier this year. Tilray has been working on its European presence extensively this year. This week the company confirmed its German cannabis cultivation facility, Aphria RX GmbH, has obtained the first new cannabis cultivation license issued under MedCanG, Germany's new Cannabis Act.
"We are proud to have received approval for our Tilray Solução Oral THC10:CBD10 product and expanding our medical cannabis offerings for patients in Portugal," said Denise Faltischek, chief strategy officer and head of international at Tilray Brands, Inc. "This is a significant step towards meeting the critical needs of patient care and providing high-quality cannabis products and therapeutic options to those with specific medical conditions. The approval of this oral cannabis solution in Portugal is a testament to Tilray's global commitment to increasing safe and regulated access to medical cannabis products for patients in need."
Tilray Medical offers a diverse portfolio of EU-GMP-certified medicinal marijuana products, and its operations extend to over 20 countries.
In 2001, Portugal became the first nation in the world to decriminalize the possession and use of all drugs, including cannabis in an effort to combat drug abuse and reduce drug-related crime. Then in 2018 it approved medical marijuana legalization and regulated it the following year. Even though medical marijuana is legal it can only prescribed to patients suffering from seven specific conditions for which other traditional treatments failed. To make things more complicated the only two medical marijuana products that were sold in Portugal until now are Tilray's 18% THC cannabis flower and Tilray Oral Solution THC 5 CBD 20.
大麻巨頭蒂爾雷品牌公司（納斯達克股票代碼：TLRY）週三宣佈，其新的醫用大麻提取物已在葡萄牙獲得第二次批准。獲得此批准的醫用大麻提取物是Tilray口服溶液THC10：CBD10。
這一里程碑是繼Tilray Medical的全花四氫大麻酚18獲得成功批准以及葡萄牙今年早些時候批准第一種大麻提取物之後發生的。今年，Tilray一直在廣泛拓展其歐洲業務。該公司本週證實，其德國大麻種植設施Aphria RX GmbH已獲得根據德國新的大麻法案MedCang頒發的第一份新的大麻種植許可證。
Tilray Brands, Inc.首席戰略官兼國際負責人丹尼斯·法爾蒂舍克說：“我們很自豪我們的Tilray Solucao口服THC10：CBD10產品獲得批准，並擴大了我們爲葡萄牙患者提供的醫用大麻產品，這是朝着滿足患者護理的關鍵需求以及爲患有特定疾病的人提供高質量的大麻產品和治療選擇方面邁出的重要一步。這種口服大麻解決方案在葡萄牙獲得批准，證明了Tilray的全球承諾，即增加有需要的患者獲得醫用大麻產品的安全和受監管的機會。”
Tilray Medical提供多元化的歐盟GMP認證藥用大麻產品組合，其業務擴展到20多個國家。
2001年，葡萄牙成爲世界上第一個將擁有和使用包括大麻在內的所有毒品合法化的國家，以打擊藥物濫用和減少與毒品有關的犯罪。然後在2018年，它批准了醫用大麻合法化，並於次年對其進行了監管。儘管醫用大麻是合法的，但它只能向患有其他傳統治療失敗的七種特定疾病的患者開處方。更復雜的是，到目前爲止，在葡萄牙銷售的僅有的兩種醫用大麻產品是蒂爾雷的18％四氫大麻酚大麻花和Tilray口服溶液THC 5 CBD 20。
